Ustekinumab, sold under the brand name Stelara among others, is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment...
38 KB (3,075 words) - 05:52, 21 October 2024
program comprising four clinical trials which compared risankizumab to ustekinumab, adalimumab and placebo in the indication of plaque psoriasis. The results...
13 KB (1,018 words) - 04:46, 6 July 2024
treatment with ustekinumab. It showed that patients who switched to guselkumab from ustekinumab did better than those who remained on ustekinumab. "Tremfya...
15 KB (1,089 words) - 18:39, 16 October 2024
urtoxazumab (INN) usistapide (USAN, INN) ustekinumab-aekn ustekinumab-auub ustekinumab-srlf ustekinumab-ttwe ustekinumab (USAN, INN) utibapril (INN) utibaprilat...
5 KB (341 words) - 23:33, 14 October 2024
bimekizumab is superior to not only adalimumab but also secukinumab and ustekinumab for the treatment of plaque psoriasis. "Bimzelx APMDS". Therapeutic Goods...
11 KB (656 words) - 16:11, 7 August 2024
Armando; Moreira, Ana Isabel (2016-05-24). "Inverse psoriasis treated with ustekinumab". BMJ Case Reports. BMJ: bcr2016215019. doi:10.1136/bcr-2016-215019....
7 KB (611 words) - 16:36, 7 April 2024
Management of Crohn's disease (section Ustekinumab)
needed] Ustekinumab (CNTO 1275) is a monoclonal antibody that suppresses cytokines IL-12 and IL-23. Originally designed to treat psoriasis, ustekinumab was...
44 KB (4,617 words) - 19:57, 12 September 2024
such as vedolizumab and natalizumab and interleukin antagonists like ustekinumab. Prior to the development of biological therapy as a modality to treat...
28 KB (3,327 words) - 19:25, 25 July 2024
received marketing authorization in 2021, and its second product, an ustekinumab biosimilar, in 2023. Products under development include biosimilars of...
11 KB (914 words) - 20:13, 22 June 2024
tocilizumab-bavi/Tofidence tocilizumab/Actemra October 2023 ustekinumab-auub/Wezlana ustekinumab/Stelara December 2023 bevacizumab-tnjn/Avzivi bevacizumab/Avastin...
97 KB (6,512 words) - 06:28, 8 October 2024
serious side effects or infections, except for mild nasal infections. Ustekinumab, approved for moderate to severe Crohn's disease in October 2016, has...
70 KB (7,889 words) - 03:18, 27 October 2024
share a common domain, p40, which is the target of the FDA-approved ustekinumab. In 2017 the US FDA approved guselkumab for plaque psoriasis. There have...
116 KB (13,058 words) - 21:40, 16 October 2024
certolizumab pegol and adalimumab, as well as the IL-12/IL-23 inhibitor ustekinumab, the IL-17A inhibitor secukinumab, and the IL-23 inhibitor risankizumab...
32 KB (3,440 words) - 01:34, 28 October 2024
is one of the therapeutic targets to treat the inflammatory diseases. Ustekinumab, a monoclonal antibody directed against this cytokine, is used to treat...
20 KB (2,186 words) - 18:02, 17 October 2024
Japan for use in treating psoriatic arthritis. The anti-IL-23 antibody ustekinumab can also be used to effectively treat psoriasis by indirectly reducing...
35 KB (3,989 words) - 13:32, 13 July 2024
Secukinumab Siltuximab Sirukumab Spesolimab Tildrakizumab Tocilizumab Ustekinumab Interleukin 5 Mepolizumab Immunoglobulin E Omalizumab Interferon Faralimomab...
7 KB (299 words) - 13:45, 27 April 2024
disease ulcerative colitis ankylosing spondylitis inhibits TNF-α human ustekinumab Crohn's disease ulcerative colitis plaque psoriasis psoriatic arthritis...
48 KB (4,964 words) - 04:26, 20 October 2024
showing superior skin clearance in a Phase III trial when compared to ustekinumab and a placebo. However, in May 2015, Amgen announced that it was ending...
9 KB (616 words) - 03:20, 14 August 2024
and Th17 T-cells. IL-12 and IL-23 signaling is blocked by the biologic ustekinumab and IL-23 is blocked by guselkumab, mirikizumab and risankizumab, medications...
142 KB (16,190 words) - 15:44, 27 October 2024
Daclizumab L04AC02 Basiliximab L04AC03 Anakinra L04AC04 Rilonacept L04AC05 Ustekinumab L04AC07 Tocilizumab L04AC08 Canakinumab L04AC09 Briakinumab L04AC10 Secukinumab...
3 KB (367 words) - 15:37, 25 January 2024
history, preferences, and the recommendations of the healthcare provider. Ustekinumab has frequently been used as a second-line therapy for AS, but it has...
56 KB (5,992 words) - 03:13, 19 October 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
24 KB (2,084 words) - 05:31, 21 October 2024
WANG, Ting-Shun; TSAI, Tsen-Fang (May 4, 2011). "Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: A case series". The Journal...
22 KB (2,022 words) - 23:16, 17 September 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
22 KB (1,812 words) - 09:08, 9 October 2024
corticosteroids. There are also reports that the monoclonal antibody ustekinumab (which blocks IL-23/ IL-12) may be effective. List of cutaneous conditions...
5 KB (535 words) - 17:39, 6 January 2022
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
17 KB (1,245 words) - 14:04, 2 September 2024
for ANTM on Oxygen. She appears in the 2012 commercial for Stelara (Ustekinumab), a plaque psoriasis treatment. English has taken part in the Seventh...
25 KB (2,117 words) - 20:58, 9 June 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
22 KB (2,581 words) - 20:03, 21 June 2024
1 9.9 3 etanercept rheumatoid arthritis Enbrel 7.2 7.6 7.9 8.0 8.1 4 ustekinumab psoriasis Stelara 2.0 2.6 3.7 5.0 6.6 5 pembrolizumab oncology Keytruda...
29 KB (281 words) - 06:29, 12 August 2024
breast cancer humanized monoclonal antibody HER2/neu (erbB2) antagonist ustekinumab Stelara psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease...
30 KB (2,882 words) - 11:11, 23 July 2024